Zydus starts supplies of its COVID-19 vaccine ZyCoV-D

2 February 2022

Indian drugmaker Zydus Cadila, part of Cadila Healthcare (BOM: 532321), today announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D, to the Indian government against its order from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Center (VTEC) at the Zydus Biotech Park in Changodar, Ahmedabad.

The group is also planning to make the vaccine available in the private market. ZyCoV-D is a three-dose vaccine administered intradermally using the painless PharmaJet needle free system, Tropis, on day 0, day 28 and day 56.

The vaccine will be priced at 265 rupees ($3.53) per dose and the applicator being offered at 93 rupees per dose excluding GST.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK